Literature DB >> 28480209

ALK on my mind: alectinib takes an early lead in managing intracranial disease in non-small cell lung cancer with ALK rearrangements.

Phu N Tran1, Samuel J Klempner2,3.   

Abstract

Entities:  

Year:  2017        PMID： 28480209      PMCID： PMC5401676          DOI： 10.21037/atm.2017.03.47

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  18 in total

1.  Phase II trial of gefitinib alone without radiation therapy for Japanese patients with brain metastases from EGFR-mutant lung adenocarcinoma.

Authors:  T Iuchi; M Shingyoji; T Sakaida; K Hatano; O Nagano; M Itakura; H Kageyama; S Yokoi; Y Hasegawa; K Kawasaki; T Iizasa
Journal:  Lung Cancer       Date:  2013-08-28       Impact factor: 5.705

2.  Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.

Authors:  Shirish M Gadgeel; Leena Gandhi; Gregory J Riely; Alberto A Chiappori; Howard L West; Michele C Azada; Peter N Morcos; Ruey-Min Lee; Linta Garcia; Li Yu; Frederic Boisserie; Laura Di Laurenzio; Sophie Golding; Jotaro Sato; Shumpei Yokoyama; Tomohiro Tanaka; Sai-Hong Ignatius Ou
Journal:  Lancet Oncol       Date:  2014-08-18       Impact factor: 41.316

3.  Differential Crizotinib Response Duration Among ALK Fusion Variants in ALK-Positive Non-Small-Cell Lung Cancer.

Authors:  Tatsuya Yoshida; Yuko Oya; Kosuke Tanaka; Junichi Shimizu; Yoshitsugu Horio; Hiroaki Kuroda; Yukinori Sakao; Toyoaki Hida; Yasushi Yatabe
Journal:  J Clin Oncol       Date:  2016-06-27       Impact factor: 44.544

4.  Alectinib induces a durable (>15 months) complete response in an ALK-positive non-small cell lung cancer patient who progressed on crizotinib with diffuse leptomeningeal carcinomatosis.

Authors:  Sai-Hong Ignatius Ou; Karen R Sommers; Michele C Azada; Edward B Garon
Journal:  Oncologist       Date:  2015-01-07

Review 5.  EGFR tyrosine kinase inhibitors versus cranial radiation therapy for EGFR mutant non-small cell lung cancer with brain metastases: a systematic review and meta-analysis.

Authors:  Yu Yang Soon; Cheng Nang Leong; Wee Yao Koh; Ivan Weng Keong Tham
Journal:  Radiother Oncol       Date:  2015-01-09       Impact factor: 6.280

6.  Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases.

Authors:  Daniel B Costa; Alice T Shaw; Sai-Hong I Ou; Benjamin J Solomon; Gregory J Riely; Myung-Ju Ahn; Caicun Zhou; S Martin Shreeve; Paulina Selaru; Anna Polli; Patrick Schnell; Keith D Wilner; Robin Wiltshire; D Ross Camidge; Lucio Crinò
Journal:  J Clin Oncol       Date:  2015-01-26       Impact factor: 44.544

7.  Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non-Small-Cell Lung Cancer.

Authors:  Shirish M Gadgeel; Alice T Shaw; Ramaswamy Govindan; Leena Gandhi; Mark A Socinski; D Ross Camidge; Luigi De Petris; Dong-Wan Kim; Alberto Chiappori; Denis L Moro-Sibilot; Michael Duruisseaux; Lucio Crino; Tommaso De Pas; Eric Dansin; Antje Tessmer; James Chih-Hsin Yang; Ji-Youn Han; Walter Bordogna; Sophie Golding; Ali Zeaiter; Sai-Hong Ignatius Ou
Journal:  J Clin Oncol       Date:  2016-10-31       Impact factor: 44.544

8.  Management of Brain Metastases in Tyrosine Kinase Inhibitor-Naïve Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer: A Retrospective Multi-Institutional Analysis.

Authors:  William J Magnuson; Nataniel H Lester-Coll; Abraham J Wu; T Jonathan Yang; Natalie A Lockney; Naamit K Gerber; Kathryn Beal; Arya Amini; Tejas Patil; Brian D Kavanagh; D Ross Camidge; Steven E Braunstein; Lauren C Boreta; Suresh K Balasubramanian; Manmeet S Ahluwalia; Niteshkumar G Rana; Albert Attia; Scott N Gettinger; Joseph N Contessa; James B Yu; Veronica L Chiang
Journal:  J Clin Oncol       Date:  2017-01-23       Impact factor: 44.544

9.  Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases.

Authors:  Tatsushi Kodama; Masami Hasegawa; Kenji Takanashi; Yuji Sakurai; Osamu Kondoh; Hiroshi Sakamoto
Journal:  Cancer Chemother Pharmacol       Date:  2014-09-10       Impact factor: 3.333

10.  Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial.

Authors:  Dong-Wan Kim; Ranee Mehra; Daniel S W Tan; Enriqueta Felip; Laura Q M Chow; D Ross Camidge; Johan Vansteenkiste; Sunil Sharma; Tommaso De Pas; Gregory J Riely; Benjamin J Solomon; Jürgen Wolf; Michael Thomas; Martin Schuler; Geoffrey Liu; Armando Santoro; Santosh Sutradhar; Siyu Li; Tomasz Szczudlo; Alejandro Yovine; Alice T Shaw
Journal:  Lancet Oncol       Date:  2016-03-11       Impact factor: 41.316
View more
  1 in total

Review 1.  Systemic therapy for brain metastases.

Authors:  Jonathan W Rick; Maryam Shahin; Ankush Chandra; Cecilia Dalle Ore; John K Yue; Alan Nguyen; Garima Yagnik; Soumya Sagar; Saman Arfaie; Manish K Aghi
Journal:  Crit Rev Oncol Hematol       Date:  2019-07-22       Impact factor: 6.312
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.